Clinical Scorecard: Advanced Crohn’s Therapies Show Similar Safety
At a Glance
| Category | Detail |
|---|---|
| Condition | Crohn's Disease |
| Key Mechanisms | Biologics and Janus kinase inhibitors |
| Target Population | Adults aged 18 to 65 years with Crohn's disease |
| Care Setting | Commercially insured patients initiating advanced therapy |
Key Highlights
- No significant differences in serious infections, venous thromboembolism, or major adverse cardiovascular events across therapies.
- Ustekinumab associated with lower risk of gastrointestinal serious infections compared to vedolizumab.
- Venous thromboembolism rates were low, approximately 1 event per 100 person-years.
- Major adverse cardiovascular events occurred at rates below 2 events per 100 person-years.
- Study included 12,245 patients treated with various advanced therapies.
Guideline-Based Recommendations
Diagnosis
- Utilize clinical criteria and imaging for diagnosis of Crohn's disease.
Management
- Consider advanced therapies including biologics and Janus kinase inhibitors based on patient-specific factors.
Monitoring & Follow-up
- Regularly monitor for serious infections and thromboembolic events during therapy.
Risks
- Assess risk factors for infections and cardiovascular events prior to initiating therapy.
Patient & Prescribing Data
Commercially insured adults aged 18 to 65 years
Broadly similar safety profiles across advanced therapies with low event rates.
Clinical Best Practices
- Implement propensity score–based adjustments for demographics and comorbidities in treatment evaluations.
- Monitor patients closely for gastrointestinal and extraintestinal infections.
- Educate patients on potential risks associated with advanced therapies.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
